Worth reading
67In focus
Scored from 4 of 5 sectionsDirection
Deterioration
Direction inferred from the company’s description.Scale
-15.8
%Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
2024 年６月期 · Full yearPrevious forecast published 2023 年８月 16 日Net Sales6,820→5,740million
-15.8%
Operating profit280→-400million
-242.9%
Ordinary income280→-400million
-242.9%
Profit attributable to owners of the parent180→-440million
-344.4%
Net income per share6.88→-16.82yen and sen
-344.5%
The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Reason for the revision
化粧品事業における中国市場向け商品の販売が、中国の景況感悪化や福島第一原発処理水の海洋放出を発端とする日本製品の買い控えの影響等により計画を大幅に下回る見込みとなった。利益面では、売上高の計画未達、健康補助食品事業の原料高騰に伴う利益率低下、広告宣伝費の投下による販売費及び一般管理費の増加が主因。
Previous-period results2023 年６月期：売上高 8,079百万円、営業利益 725百万円、経常利益 727百万円、親会社株主に帰属する当期純利益 451百万円、１株当たり当期純利益 17.27円 銭
Dividend forecast revision変更はございません
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥6,820 million → ¥5,740 million（-15.8%） |
| Operating profit | ¥280 million → ¥-400 million |
| Ordinary income | ¥280 million → ¥-400 million |
| Profit attributable to owners of the parent | ¥180 million → ¥-440 million |
| Net income per share | 6.88 yen and sen → -16.82 yen and sen |
| Fiscal Period Covered | 2024 年６月期 |
| Period Covered | Full year |
| Publication date of previous forecast | 2023 年８月 16 日 |
| Previous-period results | 2023 年６月期：売上高 8,079百万円、営業利益 725百万円、経常利益 727百万円、親会社株主に帰属する当期純利益 451百万円、１株当たり当期純利益 17.27円 銭 |
| Reason for the revision | 化粧品事業における中国市場向け商品の販売が、中国の景況感悪化や福島第一原発処理水の海洋放出を発端とする日本製品の買い控えの影響等により計画を大幅に下回る見込みとなった。利益面では、売上高の計画未達、健康補助食品事業の原料高騰に伴う利益率低下、広告宣伝費の投下による販売費及び一般管理費の増加が主因。 |
| Dividend forecast revision | 変更はございません |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
Details and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品事業で、中国の景況感悪化や福島第一原発処理水の海洋放出を発端とする日本製品の買い控えにより、中国市場向け商品の販売が計画を大幅に下回る見込みとなったため。利益面では、売上高の計画未達に加え、健康補助食品事業の原料高騰による利益率低下と、広告宣伝費の投下による販売費及び一般管理費の増加が理由とされている。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.